The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
Sterling Commerce, Inc. (an AT&T Inc. company)
Advised AT&T Inc., a premier communications holding company, on its sale of Sterling Commerce, Inc., an enterprise software and services provider, to IBM Corporation, a global IT products and services provider
Medegen, Inc
Advised Medegen, Inc., a medical device company that develops, manufactures and markets clinically superior disposable intravenous therapy products on its sale to CareFusion, a global medical devices company
Heartscape Technologies, Inc.
Advised Heartscape Technologies, a medical device company on its sale of substantially all its assets to Roper Industries, a diversified growth company
Enzon Pharmaceuticals, Inc.
Advised Enzon Pharmaceuticals, Inc., a biopharmaceutical company on the sale of its specialty pharmaceutical business to Sigma-Tau, an Italian pharmaceutical company
Monogram Biosciences, Inc.
Advised LabCorp on the acquisition of Monogram Biosciences, a molecular diagnostics company focused on guiding and improving the treatment of serious infectious diseases and cancer
Genentech, Inc.
Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of the outstanding publicly held interest in Genentech, Inc., a leading biotechnology company
Scholastic Corporation’s US direct-to-home continuities business
Advised Scholastic, the global children’s publishing, education and media company, on the sale of its US direct-to-home continuities business to Sandvik AS
Applied Biosystems Group
Provided fairness opinion to the Board of Directors of the Applera Corporation on the merger of its Applied Biosystems business, which serves the life science industry, with the Invitrogen Corporation, creating a global leader in biotechnology reagents and systems
Ventana Medical Systems, Inc.
Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of Ventana Medical Systems, Inc., a US based provider of histopathology diagnostic equipment
ALM Media Group Holdings, Inc.
Advised Incisive Media, a portfolio company of Apax Partners, on the acquisition of ALM Media, a leading integrated media company focused on the legal and real estate sectors and the largest provider of B2B information to the US legal market
BCE Inc.
Advised the Board of BCE on a review of a range of strategic alternatives that culminated in an agreement to sell to a consortium consisting of Teacher's Private Capital, Providence Equity Partners and Madison Dearborn Partners for $52.0 billion that was ultimately terminated
Jane’s Information Group
Advised The Woodbridge Company Limited, the holding company for the Thomson family’s investments, on the sale of Jane’s Information Group, a world-leading provider of information and analysis on global defence and security, to IHS Inc.
Cardinal Health, Inc., Pharmaceutical Technologies and Services division
Provided fairness opinion to the board of directors of Cardinal Health, Inc., a global company serving the health-care industry, on the sale of its Pharmaceutical Technologies and Services business, which provides outsourced services and proprietary technologies to the global pharmaceutical and biotechnology industries
Kos Pharmaceuticals, Inc.
Advised Kos Pharmaceuticals, Inc., a specialty pharmaceutical provider of cardiovascular and respiratory drugs, on its sale to Abbott Laboratories
Verizon Communications Inc.
(various assets)
Provided independent valuation services in connection with the acquisition by América Móvil and Telmex of a 100% stake in Verizon Dominicana, an approximate 52% stake in Telecomunicaciones de Puerto Rico and an approximate 28.5% stake in Compania Anónima Nacional Teléfonos de Venezuela
IIR
Advised T&F Informa on the acquisition of IIR, a leading provider of performance improvement solutions and organiser of conferences and exhibitions. The acquisition is to be financed via a rights issue of c.$570mm and a new debt facility